Cystic Fibrosis Research

Cystic fibrosis (CF) is a common inherited disease that mostly affects the lungs and airways of a sufferer. One of the main pathological characteristics of CF is the failure of airway defence against bacterial infection, leading to frequent chest infection and progressive lung damage.

Cystic Fibrosis Research Products Targets

Products for Cystic Fibrosis Research - Page 5

Cat.No. Product Name Information/Activity
BCC2520 AEE788 (NVP-AEE788) AEE788 is an inhibitor of the EGFR and ErbB2 with IC50 values of 2 and 6 nM, respectively.
BCC1051 AG-18 Tyrphostin 23 (Tyrphostin A23) is an EGFR inhibitor with an IC50 and Kiof 35 and 11 μM, respectively.
BCC2193 AG-490 AG-490 is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.
BCC6722 AG 494 Potent EGFR-kinase inhibitor
BCC6721 AG 555 AG 555, a potent antiretroviral drug, is a potent and selective inhibitor of EGFR and blocks Cdk2 activation.
BCC6720 AG 556 EGFR-kinase inhibitor
BCC7113 AG 825 AG-825 (Tyrphostin AG-825) is a selective and ATP-competitive ErbB2 inhibitor which suppresses tyrosine phosphorylation, with an IC50 of 0.35 μM. AG-825 displays anti-cancer activity. AG825 significantly accelerates apoptosis of human neutrophils. AG-825 is a potential agent for overcoming Mn-induced neurotoxicity or AD development.
BCC4514 Tyrphostin AG 879 Tyrphostin AG 879 (AG 879) is a tyrosine kinase inhibitor that inhibits TrKA phosphorylation (IC50 of 10 μM), but not TrKB and TrKC. Tyrphostin AG 879 is also a selective ErbB2 tyrosine kinase inhibitor with an IC50 of 1 μM, and has at least 500-fold higher selectivity to ErbB2 than EGFR. Tyrphostin AG 879 has anticancer activity.
BCC6667 AG 99 (E)-AG 99 ((E)-Tyrphostin 46; (E)-Tyrphostin AG 99) is a potent EGFR inhibitor.
BCC5120 AV-412 free base AV-412 free base (MP-412 free base) is an EGFR inhibitor with IC50s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively.